MLH1 and familial pancreatic carcinoma: For individuals with mutations in BRCA1/2, ATM, PALB2, MLH1, or MSH2, screening is recommended only if there is at least one first-degree relative with pancreatic cancer; it should start at age 45–50 or 10 years younger than the youngest relative diagnosed with PDAC [38].